Jiangsu Vcare Completes Full Patient Enrollment for Phase II Clinical Trial of VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
Published Time:
2025-07-31 18:28
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
The ongoing study is a multicenter, randomized, double-blind, vehicle-controlled Phase II clinical trial evaluating the efficacy and safety of VC005 gel in adult with mild-to-moderate AD. It aims to assess the gel's efficacy and safety profile in this patient population. The primary efficacy endpoint is the change from baseline in the Eczema Area and Severity Index (EASI) score at Week 8 of treatment.
VC005 gel demonstrated excellent safety and significant efficacy in the completed Phase I clinical study . Concurrently, patient enrollment is actively underway for the Phase III clinical trial of VC005 tablets for the treatment of moderate-to-severe AD.
About VC005
VC005 is a novel, potent, highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug is under clinical development for the treatment of inflammatory and autoimmune diseases such as atopic dermatitis, ankylosing spondylitis, and rheumatoid arthritis. Compared to the currently marketed leading drug Upadacitinib, VC005 exhibits lower JAK2 inhibitory activity (based on in-vitro-kinase-assay results). This profile may potentially mitigate a series of safety concerns associated with excessive JAK2 inhibition in the clinical setting. Furthermore, synergistic efficacy exist between JAK1 and JAK3/TYK2 across multiple diseases. Therefore, while achieving high selectivity for JAK1 versus JAK2, VC005 holds the potential to deliver superior clinical efficacy compared to drugs in its class.
About Atopic Dermatitis (AD)
Atopic Dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized primarily by dry skin, intense pruritus (itching), and eczematous rashes, severely impacting patients' quality of life. The global AD patient population is estimated at approximately 230 million. The prevalence of adult AD in China is about 2%–8%, affecting over 70 million people. Among these patients, 67% have mild disease and 33% have moderate-to-severe disease. Frost & Sullivan (F&S) predicts the disease population will continue to grow at a Compound Annual Growth Rate (CAGR) of 1.7% from 2025 to 2030. Traditional therapies, such as corticosteroids, are associated with numerous adverse effects and unlikely to yield long-term advantages, making effective and stable disease control challenging. Topical JAK1 small-molecule targeted inhibitors, belonging to the class of non-corticosteroid immunosuppressants, offer the potential to preserve therapeutic efficacy while further enhancing the medication safety profile for patients with mild-to-moderate AD.
Related News
06
2017
/
06
Leaders of Management Committee of Rudong Coastal Economic Development Zone Visited Jiangsu Vcare
Leaders of management committee of Rudong coastal economic development zone visited Jiangsu Vcare on June 1st, 2017. The delegation was received by the vice chairman Jun Qu, general manager Yongqiang Liu, and vice general manager Yanchun Gong of Vcare. The delegation visited the Vcare's chemical research center and drug research center. Mr. Liu introduced R&D progress and advanced equipment to the guests. During the discussion, Mr. Liu introduced the overall development plan of Yatai Group's pharmaceutical industry, and Vcare's development history and the future plan. Mr. Liu also introduced the progress of innovative drug Vicagrel and a series of generic drugs in detail. The leaders of Rudong coastal economic development zone introduced the planning of their park, local investment, environmental protection policies and etc., and expressed their confidence in the research and development prospects of Vcare.
View Details
15
2017
/
05
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare on May 12, 2017. The general manager Yongqiang Liu received the delegation.
View Details
24
2017
/
04
Jiangsu Vcare Held Mountain Climbing and Tug-of-war Competitions
Jiangsu Vcare organized mountain climbing and tug-of-war activities recently. The mountain climbing competition was divided into men's and women's groups, and each group competed for top three. The venue was located in Laoshan National Forest Park. Everyone climbed the top after efforts. Four teams consisting of Vcare’s two R&D center members conducted a tug-of-war competition after going down the mountain and finally "Lingya team" won the top spot. Everyone had fun.
View Details
30
2017
/
03
Jiangsu Vcare Held the First Quarter Fire Drill
In order to further improve the safety awareness of new employees, Jiangsu Vcare held a fire-fighting exercise on March 30, 2017. New employees had a deeper understanding of fire extinguishers through on-site explanation of the types, inspection methods and instructions of fire extinguishers. Everyone learned about fire-fighting procedures and the use of appliances. The exercise provided a safety guarantee for everyone’s life and work.
View Details
27
2017
/
03
Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare
The delegation of Political Consultative Conference of Wenzhou Ouhai District, accompanied by vice chairman of Political Consultative Conference of Pukou Economic Development Zone visited Jiangsu Vcare Pharmaceutical Technology Co., Ltd. on the afternoon of March 27, 2017. Yongqiang Liu, the general manager of Jiangsu Vcare received the delegation. Mr. Liu introduced the company's development history and R&D progress. He focused on the progress of phase II clinical trials and the future market prospect of innovative drug Vicagrel. The delegation highly recognized Vcare's advanced equipment and facilities, harmonious human environment and comprehensive research and development capabilities.
View Details
14
2017
/
03
Jiangsu Vcare Held “Firefighting and First Aid” Training
Jiangsu Vcare invited Lei Wang, a special instructor of Nanjing Anqu Fire Education Center to give a “Firefighting and First Aid” course to new employees on March 14, 2017 and 26 new employees participated in the training. Mr. Wang collected a large number of fire cases and carefully analyzed the causes of these fires. He taught everyone how to deal with fires. His explanations made everyone fully aware of the importance and urgency of fire safety. At the same time, everyone had a better understanding of various fire extinguishers and their instructions.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn